Literature DB >> 12203085

Development of multicentric hepatocellular carcinoma after completion of interferon therapy.

Soo Ryang Kim1, Toshiyuki Matsuoka, Yoko Maekawa, Yoshihiko Yano, Susumu Imoto, Masatoshi Kudo, Shigeyuki Shintani, Kenji Ando, Keiji Mita, Katsumi Fukuda, Toshihiro Koterazawa, Miyuki Nakaji, Hirotsugu Ikawa, Toshiaki Ninomiya, Ke Ih Kim, Midori Hirai, Yoshitake Hayashi.   

Abstract

We report a case of multicentric hepatocellular carcinoma that developed in a 74-year-old man 3 and 6 years after interferon (IFN) treatment for chronic hepatitis C, despite sustained virologic, biochemical, and histological improvement. Initially, serum hepatitis C virus RNA was positive and the patients' serum level of alanine aminotransferase (ALT; 82 IU/ml) was abnormal. Hepatitis B virus (HBV) in the serum was negative for surface antigen, surface antibody, core antibody, and DNA. The patient was started on 10 x 10(6) international units (IU) of IFNalpha, 3 days a week for a total of 24 weeks. After the IFN therapy, the patient demonstrated a normal serum ALT level, and was continuously negative for HCV-RNA, and histology improved from chronic active hepatitis to chronic persistent hepatitis. Follow-up studies with ultrasonography (US) every 3 months and computed tomography (CT) every 6 months revealed no space-occupying lesion (SOL) for 3 years after IFN treatment.US-guided biopsies of two 15-mm hypoechoic SOLs in segments eight (S8) and seven (S7) 34 and 74 months, respectively, after IFN treatment showed well-differentiated hepatocellular carcinoma (HCC). Clinical data, imaging studies, and histologic examinations showed that both tumors were multicentric HCC. Further studies may provide insights into the possible role of HCV in hepatocarcinogenesis in patients demonstrating HCV eradication by IFN treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203085     DOI: 10.1007/s005350200106

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  2 in total

1.  Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy.

Authors:  Yuko Nagaoki; Hiroshi Aikata; Daisuke Miyaki; Eisuke Murakami; Yoshimasa Hashimoto; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Shintaro Takaki; Akira Hiramatsu; Koji Waki; Michio Imamura; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2011-03-04       Impact factor: 7.527

2.  Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.

Authors:  Toshie Mashiba; Kouji Joko; Masayuki Kurosaki; Hironori Ochi; Yukio Osaki; Yuji Kojima; Ryo Nakata; Tohru Goto; Akahane Takehiro; Hiroyuki Kimura; Akeri Mitsuda; Chiharu Kawanami; Yasushi Uchida; Chikara Ogawa; Atsunori Kusakabe; Ryuichi Narita; Yasushi Ide; Takehiko Abe; Keiji Tsuji; Tadashi Kitamura; Kazuhiko Okada; Tetsuro Sohda; Masaya Shigeno; Takashi Satou; Namiki Izumi
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.